Population
Patients with hypertension or chronic stable angina pectoris
Design
Review
Authors
Loading...
Significant CYP interactions limit mibefradil despite BP and angina benefits; leaves open whether selective T-type blockade is feasible without such liabilities.
Mibefradil is a novel T-type calcium channel blocker effective for hypertension and angina, but its use is limited by significant CYP450-mediated drug interactions.
Ernst et al. (1998) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: